Kevin C. O'connor

Family Medicine

3301 New Mexico Ave NW Ste 336
Washington, DC 20016

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 140 publications

Generation of Monoclonal Autoantibodies From Myelin Oligodendrocyte Glycoprotein-Specific Human B Cells Using an Optofluidic-Based Platform.

Generation of Monoclonal Autoantibodies From Myelin Oligodendrocyte Glycoprotein-Specific Human B Cells Using an Optofluidic-Based Platform.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: April 29, 2026

Failure of early B cell tolerance and possible BCR signaling dysregulation underlie NF155-mediated autoimmune nodopathies.

Failure of early B cell tolerance and possible BCR signaling dysregulation underlie NF155-mediated autoimmune nodopathies.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 20, 2026

Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells.

Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells.

Journal: Research square

Published: March 27, 2026

Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells.

Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells.

Journal: Research square

Published: March 27, 2026

Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models.

Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models.

Journal: Nature communications

Published: March 11, 2026

IgG4 on the dance floor: Partners swapped by Fab-arm exchange.

IgG4 on the dance floor: Partners swapped by Fab-arm exchange.

Journal: Science immunology

Published: March 06, 2026

Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod.

Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: December 23, 2025

Patient-Derived Monoclonal Myelin Oligodendrocyte Glycoprotein Autoantibodies Mediate Cytotoxicity.

Patient-Derived Monoclonal Myelin Oligodendrocyte Glycoprotein Autoantibodies Mediate Cytotoxicity.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: December 17, 2025

Off-target reactivity in clinical monoclonal antibodies.

Off-target reactivity in clinical monoclonal antibodies.

Journal: Structure (London, England : 1993)

Published: November 12, 2025

B cell tolerance checkpoint function in multiple sclerosis and transient CD52 depletion.

B cell tolerance checkpoint function in multiple sclerosis and transient CD52 depletion.

Journal: Journal of neuroimmunology

Published: October 28, 2025

Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology.

Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: October 21, 2025

Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.

Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.

Journal: Neurology

Published: September 26, 2025

Showing 1-12 of 140

Last Updated: 09/26/2026